A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Restless legs syndrome
  • Focus Pharmacokinetics; Registrational
  • Sponsors GlaxoSmithKline; XenoPort
  • Most Recent Events

    • 07 Jun 2016 Results of pooled analysis of three trials (NCT00298623, NCT00365352 and NCT01332305)published in the Clinical Therapeutics
    • 19 Apr 2016 Results of pooled post hoc analysis of 3 Phase III trials (NCT00298623, NCT00365352, NCT01332305) published in the CNS Drugs
    • 11 Apr 2016 Results of three phase III studies published in the CNS Drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top